Open Heart 2016 10;3(1):e000140. Epub 2016 Jun 10.
Health Economics and Health Technology Assessment , Institute of Health & Wellbeing, University of Glasgow , Glasgow , UK.
Download full-text PDF
Heart 2015 Feb 16;101(3):201-8. Epub 2014 Oct 16.
Health Economics and Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK.
Objectives: A policy model is a model that can evaluate the effectiveness and cost-effectiveness of interventions and inform policy decisions. In this study, we introduce a cardiovascular disease (CVD) policy model which can be used to model remaining life expectancy including a measure of socioeconomic deprivation as an independent risk factor for CVD.
Design: A state transition model was developed using the Scottish Heart Health Extended Cohort (SHHEC) linked to Scottish morbidity and death records. Read More
J Manag Care Pharm 2013 Mar;19(2):102-14
Department of Social, Behavioral, and Administrative Science, Touro University College of Pharmacy, 1310 Club Dr., Mare Island, Vallejo, CA 94592, USA.
Background: It has been demonstrated in previous studies that pharmacist management of patients with type 2 diabetes mellitus (T2DM) in the outpatient setting not only improves diabetes-related clinical outcomes such as hemoglobin A1c but also blood pressure (BP), total cholesterol (TC), and quality of life. Improved control of BP and TC has been shown to reduce the risks of cardiovascular disease (CVD), which has placed a heavy economic burden on the health care system. However, no study has evaluated the cost-effectiveness of pharmacist intervention programs with respect to the long-term preventive effects on CVD outcomes among T2DM patients. Read More
JAMA 1996 Mar;275(11):858-65
Northwestern University Multipurpose Arthritis and Musculoskeletal Diseases Center, Chicago, IL 60611, USA.
Objective: To quantify the trade-off between the expected increased short- and long-term costs and the expected increase in quality-adjusted life expectancy (QALE) associated with total hip arthroplasty (THA) for persons with functionally significant hip osteoarthritis.
Design: A cost-effectiveness study was performed from the societal perspective by constructing stochastic tree, decision analytic models designed to estimate lifetime functional outcomes and costs of THA and nonoperative managements.
Main Outcome Measures: A modified four-state American College of Rheumatology functional status classification was used to measure effectiveness. Read More
Clin Ther 2009 Dec;31(12):2919-30; discussion 2916-8
Graduate School of Public Health, Institute of Health Services Research, Yonsei University, Seoul, Korea.
Background: Although hyperlipidemia is well recognized as a risk factor for cardiovascular disease (CVD), there has been no appraisal of the economic impact of statin therapy in Korea.
Objective: The aim of this model analysis was to determine the cost-effectiveness of statin therapy versus no treatment for the primary prevention of CVD over a lifetime in Korea, from a health care system perspective.
Methods: We developed the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions (KIMCHI), an epidemiologic and economic Markov model of first-onset CVD in Korea in which all individuals began the simulation in the health state alive without CVD, and moved among the 4 health states (alive without CVD, alive with CVD, dead from CVD, and dead from non-CVD causes) in yearly cycles for any specified time horizon, up to 40 years. Read More